Table 2.

Estimated MPC in FIB4 and HBV-DNA viral load over time, using linear mixed model separately (univariate) and jointly (bivariate).

Cohort		Treated		Untreated		Treated vs Untreated
		MPC (95% CI)	P	MPC (95% CI)	P	P
Univariate linear mixed model
Full (n = 766)	Viral load (IU/ML)
	< 5 months	−31.8% (−44.2%, −16.6%)	< 0.001	6.2% (−27.3%, 55.2%)	0.756	0.043
	5–28 months	−1.4% (−3.0%, 0.3%)	0.110	−2.5% (−4.7%, −0.1%)	0.039	0.448
	> 28 months	−1.5% (−2.6%, −0.3%)	0.013	−1.3% (−2.8%, 0.3%)	0.121	0.834
	FIB4
	< 5 months	0.2% (−2.4%, 2.8%)	0.887	−0.8% (−4.4%, 3.1%)	0.696	0.685
	5–28 months	−0.5% (−0.9%, −0.2%)	< 0.001	0.3% (−0.2%, 0.7%)	0.216	0.003
	> 28 months	0.1% (−0.2%, 0.3%)	0.619	0.7% (0.4%, 1.0%)	< 0.001	0.003
Sub-cohort* (n = 666)	Viral load (IU/ML)
	< 5 months	−34.7%(−47.3%,−19.1 %)	< 0.001	7.6%(−29.8%, 64.9%)	0.737	0.041
	5–28 months	−1.5%(−3.2%, 0.3%)	0.098	−2.3%(−5.1%, 0.4%)	0.098	0.603
	> 28 months	−1.4%(−2.6%,−0.3%)	0.017	−1.4%(−3.1%, 0.4%)	0.139	0.949
	FIB4
	< 5 months	−0.2%(−2.9%, 2.5%)	0.862	−1.6%(−5.8%, 2.7%)	0.455	0.628
	5–28 months	−0.5%(−0.9%,−0.2%)	0.002	0.4%(−0.2%, 0.9%)	0.162	0.005
	> 28 months	0.1 %(−0.1%, 0.4%)	0.360	0.8% (0.4%,1.2%)	< 0.001	0.005
Bivariate linear mixed model
Full (n = 766)	Viral load (IU/ML)
	< 5 months	−31.8% (−43.8%, −17.4%)	< 0.001	5.7% (−26.2%, 51.3%)	0.762	0.035
	5–28 months	−1.7% (−2.8%, −0.5%)	0.004	−3.1% (−4.9%, −1.3%)	< 0.001	0.184
	> 28 months	−1.4% (−2.5%, −0.2%)	0.019	−1.1% (−2.7%, 0.5%)	0.162	0.809
	FIB4
	< 5 months	0.4% (−2.2%, 3.0%)	0.784	−0.2% (−3.8%, 3.6%)	0.919	0.811
	5–28 months	−0.5% (−0.8%, −0.3%)	< 0.001	0.1% (−0.3%, 0.4%)	0.668	0.003
	> 28 months	0.1% (−0.2%, 0.3%)	00.616	0.9% (0.7%, 1.2%)	< 0.001	< 0.001
Sub-cohort* (n = 666)	Viral load (IU/ML)
	< 5 months	34.8% (−46.9%, −20.0%)	< 0.001	6.9% (−28.4%, 59.8%)	0.743	0.031
	5–28 months	−1.8% (−2.9%, −0.6%)	0.004	−3.2% (−5.2%, −1.1%)	0.003	0.244
	> 28 months	−1.4% (−2.5%, −0.2%)	0.024	−1.2% (−3.0%, 0.6%)	0.191	0.877
	FIB4
	< 5 months	0.0% (−2.6%, 2.8%)	0.977	−1.1% (−5.3%, 3.2%)	0.604	0.650
	5–28 months	−0.5% (−0.8%, −0.3%)	< 0.001	0.1% (−0.2%, 0.5%)	0.465	0.003
	> 28 months	0.1% (−0.1%, 0.4%)	0.345	1.0% (0.7%, 1.4%)	< 0.001	< 0.001

^*Sub-cohort excludes “never immunologically active” patients (no ALT > 2*ULN or viral load > 2000 lU/mL from index date to last observation). The test for difference of MPC between treated and untreated group is reported in the last column

ALT, alanine aminotransferase; FIB4, Fibrosis-4 Index; HBV-DNA, hepatitis B virus DNA; MPC, monthly percentage change.